# TGF-β and Smads

> TGF-β sends its message through a short relay. The ligand brings two receptor kinases together, the type II kinase phosphorylates the type I kinase, the type I kinase phosphorylates a Smad, and the Smad, joined by Smad4, changes which genes are read. The same relay stops many healthy epithelial cells from dividing and helps late tumours, so this lesson also asks why one signal gives different answers in different cells. Afterwards you can trace the phosphorylation steps from receptor to Smad, sort the family into its TGF-β and BMP branches, and explain the pathway's brakes and its opposite roles in early and late cancer.

Course: Cell Signaling (Receptors with enzymes attached). Level: advanced university and graduate. About 11 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/tgf-beta-and-smads/

Builds on: Receptor Tyrosine Kinases · Cytokine Receptors and JAK–STAT · Ubiquitin and Regulated Proteolysis as Signals

## What you'll learn

- Describe the two-receptor relay: the ligand brings a type II and a type I serine/threonine kinase receptor together, type II phosphorylates type I, and type I phosphorylates a Smad.
- Trace a receptor-activated Smad through its partner Smad4 to a gene, and sort the family into its TGF-β and activin branch (Smad2, Smad3) and its BMP branch (Smad1, Smad5, Smad8).
- Explain why the same signal gives different answers in different cells, including why TGF-β restrains early tumours and helps late ones.
- Explain the brakes on the pathway (a latent ligand, inhibitory Smads, ubiquitin ligases) and connect a broken component to a disease.

**Transforming growth factor beta (TGF-β) sends its message through a short relay: the ligand brings two receptor kinases together, the type II kinase phosphorylates the type I kinase, the type I kinase phosphorylates a Smad, and the Smad, joined by Smad4, goes to the nucleus and changes which genes are read.** The same relay tells many healthy epithelial cells to stop dividing and tells fibroblasts to make collagen, and in late cancer it can work for the tumour. The name, transforming growth factor β, records a soft-agar assay from around 1980 in which the protein, helped by epidermal growth factor (EGF), made normal cells grow like cancer cells, and it hides the stop-dividing job. This lesson follows the relay first and then asks why one signal gives different answers in different cells.

## The idea: the ligand only introduces two kinases

The insulin and epidermal growth factor (EGF) receptors from the receptor field guide are tyrosine kinases. Transforming growth factor beta (TGF-β) receptors are receptor serine/threonine kinases: each crosses the membrane once, and its inner part is a kinase that puts phosphate on serine or threonine. Humans have five type II receptors and seven type I receptors, shared among more than thirty related ligands: the TGF-βs, the activins, the bone morphogenetic proteins (BMPs) and others.

TGF-β itself is a dimer, two chains joined by a disulfide bond. Here is what it does:

1. The dimer binds two type II receptors. (TGF-β2 binds type II weakly and gets help from a co-receptor, betaglycan.) The type II kinase is active before any ligand arrives, and it stays active.
2. The ligand and type II together recruit two type I receptors, so four receptor chains surround one ligand.
3. Type II phosphorylates type I on a stretch just inside the membrane called the GS domain, named for its glycines and serines.
4. The type I kinase, now active, phosphorylates the next protein in line, a Smad.

> **TGF-β + type II + type I → type II phosphorylates the GS domain of type I → type I phosphorylates a Smad**

Think of type II as a lit match and type I as a fuse. The ligand’s only job is to hold the match to the fuse.

*Figure (AI-generated illustration).* The ligand binds two type II receptors first, then brings in two type I receptors. The always-active type II kinase phosphorylates the GS domain of type I, and the now-active type I kinase phosphorylates a Smad: the ligand's only job is to hold the match to the fuse. Image: four frames of the TGF-beta receptor at the membrane. 1: the ligand dimer sits on two type II chains while two type I chains stand apart. 2: the two type I chains join, so four chains surround one ligand. 3: an arrow runs from a type II kinase to the GS domain of the neighbouring type I chain, which now carries two phosphates. 4: the type I kinase puts two phosphates on the tail of a Smad.

Jeffrey Wrana and Liliana Attisano worked this out in Joan Massagué’s laboratory between 1992 and 1994. First they showed that the type II receptor binds TGF-β but cannot signal without type I, and that type I cannot bind TGF-β without type II. Then they showed that phosphorylation runs one way, from the kinase that never turns off to the kinase that cannot start alone.

What keeps the fuse from lighting by accident? In a resting type I receptor the unphosphorylated GS domain holds the kinase in an inactive shape, and a small protein called FKBP12 sits on top of it. Phosphorylation by type II ends that arrangement and turns the GS domain into a docking site for Smads.

The pairing also decides which ligand a cell can hear. Attisano’s 1993 paper found that different pairings of a type I with a type II receptor gave complexes with different signaling capacities, so a cell answers only the ligands for which it displays a working pair. (Some relatives, such as BMP2, grip type I more tightly than type II, but the phosphate still passes from type II to type I.)

## The messenger is the transcription factor

In the cAMP and Ras pathways several proteins stand between the receptor and a gene. Here there is one. The protein that the type I receptor phosphorylates is itself a transcription factor, a protein that binds DNA, on its own or in a complex, and changes how often a gene is read.

These proteins are the Smads, named for two genes found in animals: sma in the worm and Mad in the fly.

Humans have eight Smads in three groups:

- **Receptor-activated Smads (R-Smads)** are the receptor’s substrates. Transforming growth factor beta (TGF-β) and activin receptors phosphorylate Smad2 and Smad3. Bone morphogenetic protein (BMP) receptors phosphorylate Smad1, Smad5 and Smad8.
- **Smad4** is the partner that both branches share.
- **Smad6 and Smad7** are inhibitory Smads, covered below with the brakes.

An R-Smad has two folded domains. The front one, MH1, binds DNA in most Smads. The back one, MH2, binds other proteins and ends in a short tail. The type I receptor phosphorylates two serines at the very end of that tail. A phosphorylated tail fits a pocket on a neighbouring MH2 domain, so R-Smads leave the receptor and assemble with Smad4, typically two R-Smads to one Smad4. The complex collects in the nucleus and binds DNA.

The signal transducer and activator of transcriptions (STATs) of the last lesson take the same shortcut, except that a STAT is phosphorylated on tyrosine by a separate kinase, a Janus kinase (JAK), while a Smad is phosphorylated on serine by the receptor itself.

The BMP branch does much of its work in shaping the embryo, which belongs to the next unit.

## Same signal, different answers

The MH1 domains of Smad3 and Smad4 read very short DNA sequences, such as the four base pairs GTCT, and they hold them weakly. (Smads also read short GC-rich sequences, which the bone morphogenetic protein (BMP) branch favours.) A sequence that short turns up by chance about once every 256 base pairs (4 × 4 × 4 × 4), which means millions of sites in a human genome. A Smad complex alone cannot pick out a gene.

It picks a gene with help. Smads usually bind firmly only next to partner transcription factors that read their own sequences nearby. Each cell type makes its own set of partners and keeps its own set of genes open for reading. The Smad complex carries one message, “transforming growth factor beta (TGF-β) is here.” The partners decide what that means in this cell.

*Figure (AI-generated illustration).* A Smad complex reads sequences too short to pick out a gene on its own; it binds firmly only beside partner transcription factors that each cell type makes for itself. The complex carries one message, that TGF-beta is here, and the partners decide what it means: stop dividing in many epithelial cells, make collagen in a fibroblast. Image: two cell nuclei side by side. The same three-block Smad complex sits on DNA in both. In the epithelial cell a clay partner factor sits beside it and the genes p15 and p21 are switched up while Myc is switched down. In the fibroblast a differently shaped partner sits beside the same complex and a collagen gene is switched up.

In many healthy epithelial cells it means “stop dividing.” Smad3 and Smad4, with their partners, switch on the genes for p15 and p21, two proteins that inhibit the cyclin-dependent kinases (the enzymes that push a cell through its division cycle). They also switch off the gene for Myc, a transcription factor that drives growth. In a fibroblast the same pathway switches on collagen genes, which is why TGF-β drives wound repair and, in excess, scarring.

This is also why the pathway has two faces in cancer, as Roberts and Lalage Wakefield set out in 2003. Early on, TGF-β acts as a tumour suppressor, because the cells still obey the stop order. Later the tumour cells no longer stop, and the TGF-β around them works in the tumour’s favour: it quiets nearby immune cells and can push tumour cells to loosen from their neighbours and move.

## Three brakes, and what breaks

**Film transcript: Three Brakes on a Strong Signal**

### Film transcript: Three Brakes on a Strong Signal

A signal this strong has to be kept off most of the time. First brake: the ligand is stored locked. TGF-β is secreted still wrapped in the front part of its precursor chain. It stays bound and covers the surfaces receptors need. It is usually tethered to the extracellular matrix. For example, a cell's integrins can pull on the wrapper, or a protease can cut it. Active ligand is released locally. Second brake: the signal makes its own inhibitor. One of the genes that Smads switch on encodes Smad7. Smad7 binds the active type I receptor, and keeps the receptor's Smads away. That is negative feedback. Third brake: the parts are destroyed. Smad7 brings ubiquitin ligases called Smurfs to the receptor.

Smurfs tag the receptor, and some Smads, with ubiquitin for destruction. Scott Kern's laboratory found Smad4. It is inactivated in about half of pancreatic cancers. Mice made without the myostatin gene, in Se-Jin Lee's laboratory, have muscles two to three times the normal weight. In fibrodysplasia ossificans progressiva, muscle and connective tissue turn to bone. Nearly all patients with the classic form carry the same one amino acid change. It sits in the GS domain of a BMP type I receptor.

A signal this strong has to be kept off most of the time.

**The ligand is stored locked.** Transforming growth factor beta (TGF-β) is secreted still wrapped in the front portion of its own precursor chain, which has been cut off but stays bound and covers the surfaces that receptors need. This latent complex is usually tethered to the extracellular matrix, the protein mesh between cells. Active TGF-β is released locally, for example when a cell’s integrins (adhesion receptors) pull on the wrapper or a protease cuts it.

*Figure (AI-generated illustration).* TGF-β is secreted in a latent complex: the cleaved front portion of its precursor remains bound and blocks receptor access. This wrapper is usually tethered to the extracellular matrix. Local activation can occur when cell integrins pull on the wrapper or a protease cuts it, releasing active TGF-β from the wrapper. Image: a gold TGF-β dimer lies within a slate precursor-derived wrapper connected to extracellular matrix fibres by a distinct tether. Two alternative activation insets show a membrane integrin pulling the wrapper against the matrix anchor, or a protease cutting the wrapper. Each shows an intact gold dimer released nearby, separated from the wrapper and matrix tether.

**The signal makes its own inhibitor.** One of the genes that Smads switch on encodes Smad7, which binds the active type I receptor and keeps R-Smads away from it. This is negative feedback, as in the signaling circuits lesson. Smad6 does a similar job, with a preference for the bone morphogenetic protein (BMP) branch.

**The parts are destroyed.** Smad7 also brings ubiquitin ligases called Smurfs (Smad ubiquitination regulatory factors) to the receptor. Smurfs tag the receptor, and some Smads, with ubiquitin for destruction, as covered in the lesson on ubiquitin and proteolysis.

**Pancreatic cancer.** Smad4 was found in 1996, in Scott Kern’s laboratory, as a gene missing from pancreatic tumours, and was first named DPC4, for deleted in pancreatic cancer. It is inactivated in about half of pancreatic cancers.

**Muscle size.** Myostatin, a TGF-β relative made by muscle, tells muscle to stop growing. Mice made without the gene in Se-Jin Lee’s laboratory in 1997 have muscles two to three times the normal weight.

**Bone in the wrong place.** In fibrodysplasia ossificans progressiva, bone progressively forms in muscle and connective tissue. Nearly all patients with the classic form carry the same single amino acid change in a BMP type I receptor called ACVR1. The change sits in the GS domain, the part of the receptor that keeps the kinase off until type II phosphorylates it.

### Design problem

TGF-β stops a healthy epithelial cell from dividing, yet many late tumours make large amounts of it. Propose two different changes in a tumour cell that would let it ignore the stop signal. For each, say whether the cell would also lose TGF-β’s other effects, and which change you would expect a tumour to gain from more.

> **One way to do it.** **Change 1: cut the relay.** Lose the type II receptor or Smad4, and the message never reaches the arrest genes. The cost is that the cell also loses most or all of its other Smad-dependent responses, including any that a tumour could use, such as the programme that lets cells move. Tumours do take this route: the type II receptor gene is inactivated in a subset of colon cancers.
>
> **Change 2: cut only the arrest arm.** Leave the receptors and Smads intact and remove what they act on: delete the p15 and p21 genes, or drive Myc so hard by another route that the Smads cannot shut it off. The cell still hears TGF-β but no longer stops, and its other responses survive.
>
> **Which helps the tumour more?** Plausibly the second, because the cell escapes the brake and keeps a signal it can turn to its own use. A cell that took the first route still benefits from the TGF-β around it, which acts on immune cells and other neighbours whose receptors are normal.

## Going deeper

### How the name was earned: the soft-agar story

Around 1980 the laboratory test for a cancer-like cell was a dish of [soft agar](https://stemhop.com/methods/clonal-and-colony-assays/). A normal fibroblast (a connective-tissue cell) divides only when it is anchored to a surface. A transformed cell, one with the habits of a tumour cell, needs no anchor and grows into a colony while suspended in the gel. De Larco and Todaro had reported that cells transformed by a sarcoma virus release something that makes normal cells pass this test. The activity was called a transforming growth factor, and the name carried an assumption: this is what cancer cells make.

At the National Cancer Institute, Anita Roberts and Michael Sporn set out to purify it. In 1980 Roberts extracted the activity from cells transformed by a virus or by chemicals. In 1981 the same kind of extraction pulled an activity that needed help from epidermal growth factor (EGF), which the authors called a new class of transforming growth factors, out of tissues of healthy adult mice, among them kidney, liver, heart and brain. Normal organs were making the “cancer” factor. In 1983 the same group showed that the original transforming activity was two proteins: TGF-α, a relative of EGF, and transforming growth factor beta (TGF-β), which made normal cells form large colonies in soft agar only when EGF or TGF-α was also present.

Then the protein was caught doing the opposite job. In 1984 Tucker, Shipley, Moses and Holley reported that a growth inhibitor from kidney epithelial cells (the cells that line surfaces such as skin and gut) was closely related to TGF-β. In 1985 Roberts, Sporn and colleagues called their purified protein “a bifunctional regulator of cellular growth”: it raised colonies in one assay and held cells back in another, depending on the cell and the conditions.

### Finding the Smads: a name from a worm and a fly

These proteins are the Smads. The name joins two genes that geneticists found in animals: sma, from the worm C. elegans, whose mutants are small, and Mad, from the fruit fly. In 1996 Macías-Silva, Wrana, Attisano and colleagues, by then in Toronto, reported that the TGF-β receptor phosphorylates a human relative they called MADR2, now Smad2. Other laboratories, Massagué’s among them, reported related Smads the same year.

### The ACVR1 change in fibrodysplasia ossificans progressiva

The change is histidine for arginine at position 206 (R206H), as the laboratory of Eileen Shore and Frederick Kaplan reported in 2006.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/tgf-beta-and-smads/
